Treatment with von Willebrand factor concentrates is generally well tolerated.1, 2

Rare cases of thromboembolic events or the development of alloantibodies have been reported with some von Willebrand factor concentrates.3, 4 No thromboembolic events or inhibitory alloantibodies have been reported in clinical trials with wilate® in people with all von Willebrand disease types.5

Tolerability of wilate®

Tolerability of wilate® has been demonstrated across 8 clinical trials in 155 patients with von Willebrand disease5 *

With 28 treatment-related adverse events reported in 17 patients

* Indication: Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.

Thromboembolic events

Treatment-related deaths

Inhibitory antibodies to von Willebrand factor

Tolerability of wilate®

Tolerability of wilate® was rated very good or good >99% of infusions6

Tolerability has been confirmed in over 15 years of experience in the real-world setting, with approximately 1.8 billion international units of wilate® distributed wordwide5

Tolerability of wilate®


  1. Castaman G and Linari S J Blood Med 2021; 12:165-75.
  2. Federici AB and James P Acta Haematol 2012; 128:88-99.
  3. Rietveld IM et al. J Thromb Haemost 2019; 17:99-109.
  4. James PD et al. Blood 2013; 122:636-40.
  5. Octapharma, data on file.
  6. Berntorp E et al. Haemophilia 2009; 15:122-30.